high of $275.40. The index is now perched above the key support level of its 200-day moving average. If this week's decline holds it will mark the seventh straight on high volume. ETFs: XBI , BIB , BBH , FBT , PBE , BIS 5 comments!
and money is flowing into consumer stapes ( XLP +0.3% ) and utilities ( XLU +0.4% ). Biotech ETFs: IBB , XBI , BIB , BBH , FBT , PBE , BIS Nasdaq ETFs: QQQ , PSQ , TQQQ , QID , SQQQ , QLD , QQEW , QQQE , QQXT , TNDQ Small-cap ETFs: IWM , TZA
QQXT , RZG , JKJ , SBB , RSCO , UKK , VIOG , VTWG , TILT , FYX , FNDA , VIOV , XSLV , FYT , SKK , JKK , PXSV , EWRS , VTWV , TNDQ , TWOK , UVT , SMLV , SJH , IESM , FYC , VLU , PXSC , PXSG , IBB , XBI , BIB , BBH , FBT , PBE , BIS 1 comment!
By Lou Basenese : For months, the experts have been duking it out about whether or not the biotech sector is in a full-blown bubble. In one corner, we have the Richard Bernsteins of the world. Even though the iShares Nasdaq Biotechnology Fund ( IBB ) essentially doubled in price over the last two
By Morgan Myrmo: Over the past two years, biotechnology has been one of the most attractive industries to invest in, as returns have been nothing short of phenomenal. In terms of the domestic stock market, the U.S. S&P Biotechnology Select Industry Index has outperformed the S&P 500 heavily. ...
heavy volume in early trading. Modest support at 235 is holding. If it fails, the next point of resistance is ~225. Money flow has been decidedly negative for the past four weeks. ETFs: XBI , BIB , BBH , FBT , PBE , BIS Post your comment!
By Intrepid Investor : In this article I discuss the value of New England Journal of Medicine (NEJM) as the single most reliable source information on clinical trials of important new drugs. I list the companies with the largest numbers of novel drugs or the most important ones that were approved
By Franklin Templeton Investments : Evan McCulloch, CFA® Vice President/Research Analyst Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group® Currently, there are many exciting products in the pharmaceutical and biotech space producing clinical data that show a meaningful
By Pater Tenebrarum : Editor’s Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks. General Remarks on Our Approach to Biotechnology First off, we should point out that when it
By Jason Napodano : This is the sixth piece in Seeking Alpha's Positioning for 2014 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond. As always, the focus is on an overall approach